Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)

This study will evaluate the safety and efficacy of a single intravitreal injection of
AGN208397 to treat Macular Edema associated with Retinal Vein Occlusion. This study is being
conducted in two stages: Stage 1 will enroll approximately 21 subjects who will receive a
single open label intravitreal injection of either 75 ug, 300 ug, 600 ug or 900 ug of
AGN208397 and be followed for 12 months post treatment; based on Stage 1 results, Stage 2
will enroll approximately 96 subjects who will receive a single masked intravitreal
injection of one of three doses of AGN208397 or Ozurdex® and be followed for 12 months post
treatment.